Financing channel feed

Chris Var­ma un­veils MP­M's lat­est start­up — eye­ing 'un­drug­gable' can­cer tar­gets and pow­ered by ma­chine learn­ing, $67M

6 years ago
Startups

Tasly Bio­phar­ma pitch­es long-await­ed IPO — will it trig­ger an­oth­er $1B gold rush on HKEX?

6 years ago
China

With 4 more biotech IPOs due to wrap up Q2, how is the class of 2019 far­ing?

6 years ago

In $86M IPO pitch, Mirum spells out plans to turn Shire dis­cards in­to or­phan liv­er drug suc­cess­es

6 years ago

Eli Cas­din backs Codex­is' plat­form tech with $50M eq­ui­ty buy

6 years ago
People

In­vestors pony up $476M for the lat­est round of biotech IPOs to hit the Street

6 years ago

Wood­ford braces po­lit­i­cal storm as UK fi­nan­cial reg­u­la­tors scru­ti­nize fund sus­pen­sion

6 years ago
People

Bob Langer's first port of call — Po­laris Part­ners — maps $400M for ninth fund

6 years ago

Pre­clin­i­cal an­ti­sense biotech, led by for­mer Sarep­ta CEO Kaye, vaults on to Nas­daq with up­sized IPO

6 years ago

David de Graaf now has his $28.5M launch round in place, build­ing a coen­zyme A plat­form in his lat­est start­up

6 years ago
Startups

Un­der siege, in­vest­ment man­ag­er Wood­ford faces an­oth­er in­vest­ment shock

6 years ago
People

Adding mar­quee in­vestors, Black­Thorn bags $76M to back an AI-dri­ven strat­e­gy for pre­ci­sion neu­ro med­i­cine

6 years ago
Startups

Fol­low­ing CAR-T pi­o­neer­s' foot­steps, Tes­sa launch­es Chi­na JV in $120M deal

6 years ago
China
Cell/Gene Tx

Or­biMed-backed Pre­lude Ther­a­peu­tics rais­es $60M to tack­le re­sis­tance to can­cer treat­ments

6 years ago
Startups

Bain’s biotech team has cre­at­ed a $1B-plus fund — with an eye to more Big Phar­ma spin­outs

6 years ago

ADC Ther­a­peu­tics beefs up mon­ster $200M round with fresh $76M haul

6 years ago

Ar­ti­zan com­pletes mi­cro­bio­me starter pack­age with Brii deal, CSO hire and some mon­ey to dash for the clin­ic

6 years ago
Startups

Han­soh grabs $1B wind­fall in the lat­est Chi­na phar­ma IPO to hit the Hong Kong ex­change

6 years ago
China

Spread­ing its wings in Chi­na with glob­al am­bi­tion, EpimAb snags $74M Se­ries B for bis­pe­cif­ic work

6 years ago
China

Neil Wood­ford force­ful­ly stems in­vestor out­flow by sus­pend­ing his be­lea­guered main fund

6 years ago
People

Weeks af­ter rais­ing $40M, Cel­gene-part­nered In­hi­brx lays ground­work for near­ly $75M pub­lic de­but

6 years ago

Quest for safe mus­carinic re­cep­tor ag­o­nists to tack­le dis­as­ter prone CNS field steers Karuna to $75M IPO

6 years ago

Luck and uni­corns? Who needs that? San­té Ven­tures’ new $250M fund is look­ing for biotech up­starts

7 years ago

Part­nered with Genen­tech and Mi­crosoft, this biotech be­lieves it can lever­age its knowl­edge of the im­mune sys­tem in­to a $230M-plus IPO

7 years ago
First page Previous page 111112113114115116117 Next page Last page
A service from the Financial Times